Aromatic Compound ER Degrader Structure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional non-steroidal estrogen receptor (ER) degraders, such as tamoxifen, have partial agonistic effects, leading to lower efficacy and incomplete blockade of estrogen-mediated activity in treating ER-related diseases.
Innovation Solution
Development of an aromatic compound represented by formula (I) or its optical isomers, salts, hydrates, or solvates, which can be used in the manufacture of ER degraders to effectively reduce ER expression at the transcript or protein level.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional non-steroidal ER degraders such as tamoxifen are used, then ER binding competition is achieved, but partial agonistic effects occur resulting in lower efficacy and incomplete blockade of estrogen-mediated activity
Solution Approach 1:
The patent modifies the chemical structure of ER degraders by changing molecular parameters - specifically incorporating steroidal core structures with modified A-rings (formula I compounds) or B-rings (formula II compounds) to eliminate partial agonistic effects while maintaining high affinity ER binding. This structural parameter change transforms the drug from having partial agonistic activity to achieving pure antagonistic activity with complete blockade.
2Reliability
If specific pure antiestrogens with high affinity for ER are developed, then complete blockade of estrogen-mediated activity is achieved, but the complexity of compound structure increases
Solution Approach 1:
The patent segments the complex ER degrader molecules into two distinct structural series: formula I compounds with modified A-rings and formula II compounds with modified B-rings. This segmentation allows systematic exploration of structural motifs while maintaining manageable complexity. Each series follows a defined structural framework that can be optimized independently for specific therapeutic applications.
Solution Approach 2:
The patent applies local quality modification by making specific changes to particular regions of the steroidal core - either the A-ring or B-ring - while maintaining the overall steroidal framework. This localized modification approach achieves pure antiestrogenic activity without requiring complete redesign of the entire molecular structure, thus managing complexity while improving efficacy.
Data Source
Figure 1~2
AI summary
The present invention provides an aromatic compound, a method for preparing same, and use thereof in the preparation of an estrogen receptor degrader, and belongs to the technical field of chemical medicines. The aromatic compound is a compound represented by formula (I), or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof. The compound of the present invention can be used for preparing an estrogen receptor degrader, and a drug for treating an estrogen receptor-associated disease, such as a drug for treating and/or preventing cancer, wherein the cancer can be breast cancer.